Metzger-Filho O - Search Results

1

Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

Saini KS, Azim HA Jr, Metzger-Filho O, Loi S, Sotiriou C, de Azambuja E, Piccart M. Saini KS, et al. Breast. 2011 Oct;20 Suppl 3:S20-7. doi: 10.1016/S0960-9776(11)70289-2. Breast. 2011. PMID: 22015288 Free article. Review.

2

Larotaxel: broadening the road with new taxanes.

Metzger-Filho O, Moulin C, de Azambuja E, Ahmad A. Metzger-Filho O, et al. Expert Opin Investig Drugs. 2009 Aug;18(8):1183-9. doi: 10.1517/13543780903119167. Expert Opin Investig Drugs. 2009. PMID: 19604119 Review.

3

Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis.

Metzger Filho O, Ignatiadis M, Sotiriou C. Metzger Filho O, et al. Crit Rev Oncol Hematol. 2011 Jan;77(1):20-9. doi: 10.1016/j.critrevonc.2010.01.011. Crit Rev Oncol Hematol. 2011. PMID: 20138540 Review.

4

Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.

Metzger-Filho O, Vora T, Awada A. Metzger-Filho O, et al. Expert Opin Investig Drugs. 2010 Apr;19 Suppl 1:S31-9. doi: 10.1517/13543781003730135. Expert Opin Investig Drugs. 2010. PMID: 20374028 Review.

5

Prevention and management of major side effects of targeted agents in breast cancer.

Metzger Filho O, Saini KS, Azim HA Jr, Awada A; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Metzger Filho O, et al. Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e79-85. doi: 10.1016/j.critrevonc.2010.07.014. Epub 2011 Mar 15. Crit Rev Oncol Hematol. 2012. PMID: 20817545 Review.

6

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.

Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, Dolci SM, Ghenne C, Metzger-Filho O, Skrzypski M, Paesmans M, Ameye L, Piccart-Gebhart MJ, de Azambuja E. Saini KS, et al. Ann Oncol. 2012 Apr;23(4):853-9. doi: 10.1093/annonc/mdr352. Epub 2011 Aug 4. Ann Oncol. 2012. PMID: 21821551 Free article.

7

Neoadjuvant chemotherapy and targeted therapies: a promising strategy.

Metzger-Filho O, de Azambuja E. Metzger-Filho O, et al. J Natl Cancer Inst Monogr. 2011;2011(43):116-9. doi: 10.1093/jncimonographs/lgr019. J Natl Cancer Inst Monogr. 2011. PMID: 22043056

8

Benefit-risk assessment of bevacizumab in the treatment of breast cancer.

Dienstmann R, Ades F, Saini KS, Metzger-Filho O. Dienstmann R, et al. Drug Saf. 2012 Jan 1;35(1):15-25. doi: 10.2165/11595910-000000000-00000. Drug Saf. 2012. PMID: 22136182 Review.

9

Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).

Azim HA Jr, Metzger-Filho O, de Azambuja E, Loibl S, Focant F, Gresko E, Arfi M, Piccart-Gebhart M. Azim HA Jr, et al. Breast Cancer Res Treat. 2012 May;133(1):387-91. doi: 10.1007/s10549-012-1996-6. Epub 2012 Feb 26. Breast Cancer Res Treat. 2012. PMID: 22367645

10

Dissecting the heterogeneity of triple-negative breast cancer.

Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M. Metzger-Filho O, et al. J Clin Oncol. 2012 May 20;30(15):1879-87. doi: 10.1200/JCO.2011.38.2010. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454417 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

64 results

Search Page